CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
belinostatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00357162
NCT00357162Phase 2Completed
CompareCT.gov

Phase II Study of the Histone Deacetylase Inhibitor PXD101 for the Treatment of Myelodysplastic Syndrome

National Cancer Institute (NCI)·interventional·Posted Jul 27, 2006·Updated May 20, 2014

In Brief

A Phase 2 clinical trial evaluating belinostat for de Novo Myelodysplastic Syndromes and 2 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This phase II trial is studying how well belinostat works in treating patients with myelodysplastic syndromes. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Conditionsde Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Secondary Myelodysplastic Syndromes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 27, 2006
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.9 years ago

Interventions

belinostatdrug

Given IV